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Abstract
Background:  Important methodological questions still exist concerning the Dexamethasone
Suppression Test (DST), including the possibility of a better way of interpreting it. The aim of the
present study was to explore the feasibility of an alternative way of interpreting DST results.
Methods: A total of 50 patients with major depression aged 41.0 ± 11.4 years old participated in
the study. Past and present suicide attempts were recorded. Psychometric assessment included the
Hamilton Depression Rating Scale (HDRS), the Hamilton Anxiety Scale (HAS), the Newcastle
Depression Diagnostic Scale (NDDS), the Diagnostic Melancholia Scale (DMS) and the General
Assessment of Functioning (GAF) scale. The 1 mg DST protocol was used. Analysis methods
included the chi square test and analysis of covariance (ANCOVA) with Fisher least significant
difference (LSD) as post hoc tests.
Results: In all, 34 patients (68%) were suppressors, 16 (32%) were non-suppressors and 14
patients had cortisol values above 5 μg/dl at baseline. Baseline cortisol level did not influence the
classical DST interpretation. A total of 18 patients (36%) showed an increase of their cortisol levels
after dexamethasone administration and 32 patients (64%) showed a decrease. Reducers had less
melancholic features, similar levels of depression, better sleep and less suicidal thoughts in
comparison to increasers. No relationship of DST to suicidality was found.
Discussion: The present study explored the pattern of cortisol response to dexamethasone
suppression and suggested an alternative way of coding and interpreting the DST on the basis of
whether the cortisol levels remain stable or increase vs decrease after the administration of
cortisol. The results put forward a complex way of understanding the relationship of the DST
results with clinical symptoms.
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Introduction
Although the dexamethasone suppression test (DST) was
first described as a biological marker for depression [1], it
has also been associated with suicidal behaviour, melan-
cholic and latter atypical features. Newer studies suggest
that the hypothalamic-pituitary-adrenal (HPA) axis dys-
regulation shows different characteristics in suicidal and
non-suicidal depressed patients [2] suggesting that DST
status should also show a difference. More recently is has
been also suggested that the DST response might differ
even within the suicidal group, since in several studies
DST non-suppression was associated with completed sui-
cide but not with suicidal attempts [3,4]. This indicates
that the relationship between the clinical manifestation
and DST is more complex, and thus more attention
should be paid to the investigation of this relationship
and especially to the association of clinical symptoms
with the different characteristics of DST.
The aim of the present study was to investigate the rela-
tionship between suicidal behaviour and the temporal
characteristics of the DST. The temporal characteristics of
the DST concerned whether non-suppression was defined
on the basis of either of 16.00 or 23.00 day 2 cortisol lev-
els, or both. The current report is complementary to a
recently published paper by Yerevanian et al. [5]; however,
these authors measured only the 16.00 cortisol level. The
data in this brief report come from a larger research
project on the neurobiology of depression, whose results
have already been published [6]; however the DST charac-
teristics reported here have not been published previ-
ously.
Materials and methods
Subjects
A total of 50 patients (15 males and 35 females) aged 21–
60 years (mean 41.0, SD 11.4)) suffering from major
depression according to the Diagnostic and Statistical
Manual of Mental Disorders, 4th edition (DSM-IV) [7],
took part in the study.
All participants provided written informed consent; 14 of
them fulfilled criteria for atypical features, 16 for melan-
cholic features and 32 for somatic syndrome (according to
the International Classification of Diseases (ICD)-10).
Nine patients did not fulfil criteria for any specific syn-
drome.
All participants were inpatients or outpatients of the Third
Department of Psychiatry, Aristotle University of Thessal-
oniki, University Hospital AHEPA, Thessaloniki Greece
and come from a study sample used in the PhD thesis of
an author (KNF). The study on this specific population
has already produced a significant number of publications
[8-18].
All participants were free of any medication for at least 2
weeks prior to the first assessment and diagnosis. In no
case was medication interrupted in order to include the
patient in the study. In addition, all participants were
physically healthy with normal clinical and laboratory
findings, including electroencephalogram and thyroid
function, and with no pathological findings from the
opthalmological examination. There was a great effort to
exclude all cases that might contribute to the production
of confounding results due to special characteristics (for
example, obesity, puerperium etc.). Additionally, a partic-
ular effort was made to exclude patients who exhibited
alcohol or nicotine abuse.
No participant fulfilled the criteria for catatonic or psy-
chotic features or for seasonal affective disorder. Addition-
ally, no patient fulfilled the criteria for another DSM-IV
axis-I disorder, except for generalised anxiety disorder and
panic disorder, and none had a past history of manic or
hypomanic episode. Axis II disorders were also registered.
All patients had history of no more than five distinct epi-
sodes including the present one (mean 1.16 ± 1.53).
It should be noted that all suicidal attempts were non-vio-
lent, and were performed by the swallowing of pills, drugs
or poison. Rather, they had an impulsive character and no
notes were prepared before attempts.
Clinical diagnosis
The Schedules for Clinical Assessment in Neuropsychiatry
version 2.0 (SCAN v 2.0))[19] and the International Per-
sonality Disorders Examination (IPDE) [20,21]were used
to assist clinical diagnosis, which was reached by consen-
sus of two examiners, according to DSM-IV criteria. The
presence of a recent suicide attempt, the presence of an
attempt ever in the past, the age of onset of depression, the
number of episodes, the number of melancholic and atyp-
ical criteria met and the number of personality disorders
diagnosed were recorded.
Laboratory testing
Laboratory tests included blood and biochemical testing,
test for pregnancy, T3, T4 and thyroid-stimulating hor-
mone (TSH), Â12 and folic acid, and electroencephalo-
gram.
Psychometric assessment
Assessment included the Hamilton Depression Rating
Scale (HDRS) and subscales [22-24], the Hamilton Anxi-
ety Scale (HAS) and subscales [24,25], the 1965 Newcastle
Depression Diagnostic Scale (1965 NDDS) [24] and 1971
Newcastle Depression Diagnostic Scale (1971 NDDS)
[24], the Diagnostic Melancholia Scale (DMS) [24] and
the General Assessment of Functioning scale (GAF)) [7]Annals of General Psychiatry 2008, 7:22 http://www.annals-general-psychiatry.com/content/7/1/22
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On the basis of clinical and psychometric data, patients
were divided into three groups. The first included those
without death thoughts (no thoughts of death at all or
wondering whether life has no meaning), the second
included those with no specific thoughts about death
(afraid that they will die or wish to die) and finally the
third included truly suicidal patients (thinking about or
planning suicide). We created a new categorical variable,
named the Death Thoughts Rating, by attributing a score
of 0 for members of the first group, 1 for the second and
2 for the third group; this is somewhat different from the
rating of the HDRS item 3.
Data concerning personal and family history and stressful 
life events
The family history method [26-28] was used for gathering
family and personal data. The Holmes questionnaire
[29]was used to search for stressful life events during the
6 months prior to the onset of the symptomatology. The
patients were carefully questioned concerning the pres-
ence of at least one first-degree predecessor with any type
of dementia.
Dexamethasone Suppression Test
The DST [1,30-35] mainly reflects the HPA axis and nore-
pinephrine activity. The 1 mg DST protocol demands the
administration of 1 mg dexamethasone taken orally at
23.00 on the first day, and determination of cortisol
serum levels simultaneously and the next day at 16.00 and
23.00. Cortisol levels expressed in μg/dl were measured by
luminance immunoassay (intra-assay reliability: 4.9%;
interassay: 7.5%). Non-suppression cut-off level was 5 μg/
dl.
Statistical analysis
The following grouping methods were used:
￿ The two classical groups, that is suppression vs non-sup-
pression on the basis of the 5 μg/dl cut-off level.
￿ Two groups on the basis of whether cortisol values
increased or decreased after dexamethasone administra-
tion (increasers vs decreasers)
￿ Groups defined by the interaction of the above two
grouping methods.
￿ Two groups defined by the presence or not of a recent
suicide attempt (within the last month).
￿ Two groups defined by the presence or not of a suicide
attempt ever in the past
￿ Three groups defined by the Death Thoughts Rating var-
iable (A: no thoughts of death, B: non-specific thoughts of
death and C: suicidal ideation).
These patient groups were compared using:
￿ Crosstabulation frequencies between groups using the
chi square test.
￿ Three analysis of covariance (ANCOVA) tests were per-
formed, with the two ways to define DST results as group-
ing variable (in a yes/no format) and a third with their
combination, and the following as dependent variables:
age at onset, number of episodes, number of melancholic
and atypical criteria met, GAF, HDRS (and its subscales:
depressed index, anxiety index, non-specific index and
sleep index) [24], HAS (and its subscales: somatic and
psychic anxiety) [24], the 1965 NDDS and 1971 NDDS
the DMS (with its subscales: endogenous and reactive axis
[24], number of total events, number of personality disor-
ders diagnosed, and Death Thoughts Rating (as described
above). In total, 20 variables were used. Age was used as
covariate. Because of the number of ANCOVAs per-
formed, the p < 0.016 level was used to define signifi-
cance. Age was used as covariate.
The Fisher least significant difference (LSD) test was used
for the post hoc comparisons. For these comparisons the
p < 0.05 level was used to define significance.
Results
In all, 34 patients (68%) were suppressors and 16 (32%)
were non-suppressors with the use of the 5 μg/dl cut-off
point. It is to be noted that 14 (28%) patients had cortisol
values above 5 μg/dl at baseline. The results of the DST
test with the patients categorised according to their base-
line cortisol values (above and below 5 μg/dl) are shown
in table 1. It is evident that the baseline cortisol level does
not seem to influence the classical DST interpretation (chi
square test, degrees of freedom = 1, p = 0.723).
Some patients showed an increase of their cortisol levels
after dexamethasone administration while others experi-
enced a reduction. The respective frequencies are shown
in table 2. There was no effect from baseline cortisol levels
(chi square test, degrees of freedom = 1, p = 0.633). In all,
18 patients (36%) showed an increase of their cortisol lev-
els. This group overlaps significantly with classical non-
suppression (table 3). However, for 12 patients (24%) the
two different classifications were not identical.
On testing the two different DST classifications with
ANCOVA, the results were as follows: for the classical DST
non-suppression (either at 16.00 or at 23.00) the
ANCOVA showed a significant effect (Wilks L = 0.199; F =Annals of General Psychiatry 2008, 7:22 http://www.annals-general-psychiatry.com/content/7/1/22
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5.632, effect = 20; error = 28; p = 0.00002). The post hoc
results are shown in table 4. For the increaser/reducer
DSTs (three groups: reducers, increased levels only once,
increased both levels), the ANCOVA showed a significant
effect (Wilks L = 0.113; F = 2.651; effect = 40; error = 54;
p = 0.0004). The post hoc results are shown in table 5.
For the combination of the two DST interpreting methods
into a single grouping variable with three levels (suppres-
sors and reducers vs non-suppressors and increasers vs
other combinations) the ANCOVA showed again a signif-
icant effect (Wilks L = 0.129; F = 2.403; effect = 40; error =
54; p = 0.001). The post hoc results are shown in table 6.
The comparison of the relationship the two DST defini-
tions have with suicidality and thoughts of death is shown
in tables 7 and 8.
Discussion
The present study explored the pattern of cortisol
response to dexamethasone suppression and suggested an
alternative way of coding and interpreting the DST on the
basis of whether the cortisol levels remain stable or
increase vs decrease after the administration of cortisol. In
the current study sample, 34 patients (68%) were suppres-
sors and 16 (32%) were non-suppressors with the use of
the classic 5 μg/dl cut-off point. The use of both the 16:00
and 23:00 day 2 cortisol values seems to be important
otherwise significant false results appear. With the use of
the new suggested increasers/reducers dexamethasone test
(IRDT), 18 patients (36%) had unchanged or showed an
increase of their cortisol levels vs 32 patients (64%) who
showed a decrease. The two classification methods over-
lap significantly but they are not identical and for 24% of
patients are classified differently. Although several
patients had high (above 5 μg/dl) baseline cortisol values,
it seems that this does not influence the post dexametha-
sone values.
The classical DST interpretation leads to the conclusion
that DST suppressors are patients that are less endog-
enous, with lower functioning, and with higher suicidal
thoughts in comparison to non-suppressors. These results
are by themselves peculiar and do not fit with the classical
definition and concept of depression. By comparison,
reducers had less melancholic features, similar levels of
depression, better sleep and less suicidal thoughts in com-
parison to increasers. Suppressors and reducers were less
endogenous and with lower depression in comparison to
non-suppressors and increasers. Since anxiety was not
assessed in the current study but several HDRS items
include a strong anxiety component, and the HDRS anxi-
ety index was calculated, it is unlikely that the presence of
anxiety is hidden behind the peculiarity of results. How-
ever, it is possible that the combined use of the two meth-
ods to interpret the DST could isolate a subgroup of
depressed patients at high risk to show suicidal behaviour.
Our current study reported that 10% of depressed patients
from the study sample had recently attempted suicide and
26% had attempted at least once in the past. Additionally,
46% were experiencing some kind of thoughts of death
and 20% were experiencing suicidal ideation at interview
time. Concerning suicidality, no method reported in the
current study, showed a strong potential in correlating
with history of suicidal acts or present suicidal ideation.
Table 1: Dexamethasone Suppression Test (DST) results with patients categorised according to their baseline cortisol values
Suppressors Non-suppressors
Baseline cortisol < 5 μg/dl (n = 36):
Day 2, 16:00 32 (88.88%) 4 (11.12%)
Day 2, 23:00 27 (75%) 9 (25%)
Either at 16:00 or 23:00 25 (69.44%) 11 (30.56%)
Baseline cortisol > 5 μg/dl (n = 14):
Day 2, 16:00 9 (64.28%) 5 (35.72%)
Day 2, 23:00 12 (85.71%) 2 (14.29%)
Either at 16:00 or 23:00 9 (64.28%) 5 (35.72%)
Overall (n = 50) 34 (68%) 16 (32%)Annals of General Psychiatry 2008, 7:22 http://www.annals-general-psychiatry.com/content/7/1/22
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DST non-suppression has originally been associated with
the endogenous, melancholic and psychotic type of
depression [36] and has been described as a highly state
dependent marker characteristic of the symptomatic
phase of the disorder [37,38]. Our results are in line with
these observations and indicate that non-suppressors in
our sample score significantly higher on the endogenous
axis of the DMS. DST non-suppression in our study, how-
ever, is also related to a higher general functioning score
(GAF), and lower scores on the depressed index of the
HDRS and in case of the death thoughts rating. This is true
when we treat all patients showing any DST non-suppres-
sion as one group; however, distinctions within the DST
non-suppressors emerge if we form separate groups
according to the temporal characteristics of DST suppres-
sion. Therefore our study indicates that the temporal char-
acteristics of DST should be taken into account when
outlining the relationship between DST and suicidal
behaviour.
Most previous studies conducted on the association of
DST non-suppression and suicidal behaviour concluded
that DST non-suppression is related to suicidal ideation
and to future suicide rather than committed suicide
[3,39]. However, most of the studies coming to this con-
clusion use only the 23:00 on day 2 cortisol levels in order
to define DST non-suppression. The results of the current
study, however, suggest that the picture is more complex.
Recent data suggest that patients with a history of suicidal
behaviour suffer a greater burden of depressive illness [40]
and this could be reflected in the DST results.
Table 2: Changes in cortisol levels after dexamethasone administration
Day 2, 16:00 Day 2, 23:00 Either or both
Baseline cortisol < 5 μg/dl (n = 36):
Increased or unchanged 12 (33.34%) 13 (30.56%) 14 (38.88%)
Increased 6 (16.67%) 10 (27.78%)
Unchanged 6 (16.67%) 1 (2.78%)
Decreased 24 (66.66%) 25 (69.44%)
Baseline cortisol > 5 μg/dl (n = 14):
Increased or unchanged 4 (28.57%) 1 (7.14%) 4 (28.57%)
Increased 4 (28.57%) 1 (7.14%)
Unchanged 0 (0%) 0 (0%)
Decreased 10 (71.43%) 13 (92.86%)
Overall (n = 50):
Increased or unchanged 16 (32%) 12 (24%) 18 (36%)
Increased 10 (20%) 11 (22%)
Unchanged 6 (12%) 1 (2%)
Decreased 34 (68%) 38 (76%)
Table 3: Relationship between increasers vs reducers and non-
suppressors vs suppressors
Non-suppressors Suppressors Total
Increasers 15 3 18
Decreasers 1 31 32
Total 16 34 50Annals of General Psychiatry 2008, 7:22 http://www.annals-general-psychiatry.com/content/7/1/22
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Table 4: Analysis of covariance (ANCOVA) post hoc test for the classical Dexamethasone Suppression Test (DST) definition
DST suppressors DST non-suppressors p Value
Mean SD Mean SD
GAF 48.74 13.97 58.13 13.65 0.021
DMS Endogenous axis 3.88 2.92 6.13 3.03 0.011
HDRS Depressive Index 10.97 2.76 8.63 2.31 0.005
Death Thoughts Rating 1.00 0.70 0.56 0.73 0.044
DMS, Diagnostic Melancholia Scale; GAF, General Assessment of Functioning; HDRS, Hamilton Depression Rating Scale.
Table 5: Analysis of covariance (ANCOVA) post hoc test for the reducers/increasers Dexamethasone Suppression Test (DST) 
definition
Fisher least significant difference (LSD) 
test, p value
Reducers (R) Single level Inreasers (SI) Both levels Increasers 
(BI)
R vs SI R vs BI SI vs BI
Mean SD Mean SD Mean SD
No of atypical 
features
0.94 0.98 1.53 0.74 1.00 1.00 0.037 NS NS
No of 
melancholic 
features
2.25 1.52 2.20 1.61 4.00 1.73 NS 0.046 NS
HDRS 26.38 5.97 23.00 3.93 29.00 3.61 0.047 NS NS
HDRS 
Depressive 
Index
10.84 2.93 8.87 2.33 10.33 2.08 0.026 NS NS
HDRS Sleep 
Index
3.41 2.11 3.47 1.46 6.00 0.00 NS 0.025 0.036
Death 
Thoughts 
Rating
1.00 0.72 0.40 0.51 1.67 0.58 0.005 0.003 NS
Baseline 
cortisol
5.16 5.70 4.18 3.23 3.80 2.75
Cortisol day 
2, 16:00
1.94 4.29 3.77 3.89 7.17 1.46
Cortisol day 
2, 23:00
1.58 2.71 5.16 3.65 7.00 1.66
HDRS, Hamilton Depression Rating Scale; NS, not significant.Annals of General Psychiatry 2008, 7:22 http://www.annals-general-psychiatry.com/content/7/1/22
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DST suppression has been associated previously with sui-
cide [4,39,41,42], and it has also been suggested that
abnormal DST has a differential relationship with differ-
ent types of suicidal behaviour although this relationship
is weak [3,43].
Investigating the different non-suppressor groups with
distinct temporal characteristics and in relation to abso-
lute cortisol levels could give deeper insight into the asso-
ciations of DST and characteristics of depression and
suicidal behaviour. However, further research on larger
numbers is necessary in this area, although it does appear
promising.
Compared to the beginnings of research on DST when it
was conceived as being related to endogenous and melan-
cholic depression [1,36], DST results according to more
contemporary research seem to suggest it is a severity
marker rather than directly related to symptomatology.
Nearly 4–10% of normal persons are reported to be DST
non-suppressors [44-46]. The reason for this is unknown,
however it has been suggested that it is due to an underly-
ing mood disorder or family history of affective disorder.
Another explanation suggests that DST reflects in fact the
degree of psychological pressure or discomfort of the sub-
ject and not a specific vulnerability or characteristic of
depression [47,48]. It seems that non-suppression is grad-
ually increasing along a continuum, which has mourning
outpatients at one pole (13% non-suppression) and
severe psychotic melancholic inpatients with psychotic
features and suicidal ideation at the opposite one (64%
non-suppression) [49]. In this frame, the percentage of
non-suppression reported in the current study (32%, with
all types of non-suppression combined) is not in contrast
with the international literature, since most patients were
outpatients. However, if DST non-suppression can be
characterised as being related to different severities of
mood disorders along a continuum, then it is also worth
Table 6: Analysis of covariance (ANCOVA) post hoc test for the combined Dexamethasone Suppression Test (DST) definition
Fisher least significant difference (LSD) 
test, p value
Suppressors and 
reducers (SR)
Other (O) Non-suppressors and 
increasers (NSI)
SR vs O O vs NSI SR vs NSI
Mean SD Mean SD Mean SD
N1971 -5.02 19.30 -0.54 14.69 -19.55 18.44 NS 0.013 0.026
End DMS 3.82 3.02 4.17 2.37 7.30 2.87 NS 0.007 < 0.001
HDRS 
depressive 
index
11.00 2.84 9.00 2.76 9.50 2.32 0.041 NS NS
DMS, Diagnostic Melancholia Scale; HDRS, Hamilton Depression Rating Scale; NS, not significant.
Table 7: Dexamethasone Suppression Test (DST) suppression vs non-suppression and increasers vs reducers rates in the different 
suicidal behaviour groups, Yates corrected chi square tests
Suppressors (n = 34) Non-suppressors (n = 16) Chi square Increasers Reducers Chi square
n % n % p Value n % n % p Value
Recent suicide attempt 5 14.70 0 0.00 0.266 2 11.11 3 9.37 0.844
Ever suicide attempt 11 32.35 2 12.50 0.135 4 22.22 8 25.00 0.825
Death thoughts rating: 0.074 0.305
No death thoughts 8 23.53 9 56.25 6 33.33 11 34.37
Non-specific thoughts of death 18 52.94 5 31.25 6 33.33 16 50.00
Suicidal ideation 8 23.53 2 12.50 6 33.33 5 15.62Annals of General Psychiatry 2008, 7:22 http://www.annals-general-psychiatry.com/content/7/1/22
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considering whether DST non-suppression should be
characterised in a more sophisticated way with attention
paid to its temporal characteristics, rather than operating
with only two groups (namely DST suppression and non-
suppression). In some studies different plasma cortisol
threshold levels are already being used to investigate more
deeply the relationship between DST non-suppression
with depression or suicide [50]. These more elaborate
classifications of DST non-suppression would allow us to
use DST to map different subtypes of depression and sui-
cidal behaviour in a more sensitive and complex way.
Conclusion
The results of our study, especially in the light of the pre-
vious literature on DST, indicate that the relationship
between DST and clinical symptomatology is very com-
plex, and also that methodological problems and contra-
dictions often halt the possibility of drawing all data and
conclusions from studies and of comparing the results.
Specific characteristics of the response to dexamethasone
administration should be taken into account in a more
complex way when analysing the relationship between
DST and clinical symptoms in order to avoid missing a
possible existing relationship.
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